NOV 23, 2019 11:13 PM PST

Drug Seeks To Target Treatment-Resistant Epilepsy

WRITTEN BY: Nouran Amin

Ever imagined a world where you cannot shower alone, drive by yourself, and even go to work in fear of having the next seizure that can incapacitate you? Unfortunately, this is the life of many patients with epilepsy—a chronic seizure condition. To bring hope, researchers at John Hopkins University found that an investigational drug called ‘cenobamate’ can reduce seizures by 55%.

Although there exists more than 20 anti-seizure drugs on the market, approximately half of epilepsy patients don’t become seizure-free on these medications. Cenobamate, which is not yet approved by the Food and Drug Administration (FDA), aims to target treatment-resistant epilepsy. In order for cenobamate to be approved, it must be safely administered and evaluated in 30,000 epileptic patients

“A quarter of the patients I treat with this drug [cenobamate] who were disabled by frequent partial-onset (focal) seizures now have been seizure-free for several years,” says lead investigator Gregory Krauss, M.D., professor of neurology at the Johns Hopkins University School of Medicine. “It is wonderful to see the improvement in many of my patients’ lives. They have improved confidence and can live more normal lives. Many can now work, and both patients and caretakers can be more independent.”

Learn more about epilepsy:

In the study, regular treatment was stimulated and clinical participants were given 100, 200 or 400 milligrams of cenobamate or a placebo pill with the cenobamate dose increasing for up to six weeks until the desired testing dose was reached. However, to meet FDA ethical standards, participants must remain on their regularly prescribed anti-seizure medication.

Findings of the study were published in The Lancet Neurology.

Source: Hopkins Medicine

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 20, 2022
Microbiology
Rapid AST: A key weapon in the fight against AMR
APR 20, 2022
Rapid AST: A key weapon in the fight against AMR
Despite the dire, well-documented risks of antimicrobial resistance (AMR), which threatens to kill 10 million people a y ...
APR 21, 2022
Cannabis Sciences
One of the most lucrative skillsets in cannabis
APR 21, 2022
One of the most lucrative skillsets in cannabis
For anyone looking for a well-compensated, in demand job in the cannabis industry, you can't go wrong with becoming an e ...
JUN 21, 2022
Cell & Molecular Biology
From sample collection straight to RT-qPCR
JUN 21, 2022
From sample collection straight to RT-qPCR
Skip the nucleic acid purification step in your cancer detection workflow. Learn more about how Thermo Fisher Scientific ...
JUN 06, 2022
Immunology
Using Antibodies to Create Potent Cancer Treatments
JUN 06, 2022
Using Antibodies to Create Potent Cancer Treatments
Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes o ...
JUN 16, 2022
Cancer
Dance/Movement Therapy Benefits Cancer Patients
JUN 16, 2022
Dance/Movement Therapy Benefits Cancer Patients
For cancer treatment, standard of care (sometimes referred to as best practice or standard therapy) defines medical trea ...
JUN 23, 2022
Cannabis Sciences
The Latest Research on Cannabis Social Equity Programs
JUN 23, 2022
The Latest Research on Cannabis Social Equity Programs
Cannabis social equity programs are designed to increase licensure and employment opportunities for lower income and BIP ...
Loading Comments...